Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $249

Benzinga Newsdesk www.benzinga.com Negative 78.9%

Neg 78.9% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $435 to $249.